Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Madrigal Pharmaceuticals Inc (NQ: MDGL )

109.04 USD -4.96 (-4.35%)
Official Closing Price Updated: 4:57 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert In
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Posit
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial
From GlobeNewswire News Releases
Madrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights
From GlobeNewswire News Releases
Madrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis Reduction
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With N
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Announces Pricing of Secondary Offering
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Promotes Rebecca Taub, M.D., Chief Medical Officer and Executive Vice President of Research & Development, to Newly Created Position of President of Research & Development
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today the promotion of Rebecca Taub, M.D., to the newly created positon of President of Research & Development. Dr. Taub has served as Chief... 
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Jim Daly has been appointed to the Company’s Board of Directors, as a Class I director, effective as of June 27, 2019. 
From GlobeNewswire News Releases
Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Paul Friedman, M.D., Chief Executive Officer of Madrigal, and Becky Taub, M.D., CMO and Executive VP, Research & Development of... 
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of Madrigal Pharmaceuticals, Inc.
Levi & Korsinsky announces it has commenced an investigation of Madrigal Pharmaceuticals, Inc. (NASDAQCM: MDGL) concerning possible breaches of fiduciary duty. To obtain additional information, go to: 
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2019 financial results and highlights: 
From GlobeNewswire News Releases
Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Thursday, April 11, 2019 at the International Liver Congress™ 2019, European Association for the Study of the Liver (EASL) in... 
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosi
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it has initiated its Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, MGL-3196... 
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2018 financial results and highlights: 
From GlobeNewswire News Releases
Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developme
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CASI Pharmaceuticals,... 
From GlobeNewswire News Releases
Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced the oral presentation of statistically significant results from a double-blind, placebo-controlled 36-week Phase 2 clinical trial in... 
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2018 financial results and described upcoming clinical events: 
From GlobeNewswire News Releases
Research Report Identifies Brookfield Asset Management, Becton, Dickinson, IPG Photonics, ASML Holding N.V, American National Insurance, and Madrigal Pharmaceuticals with Renewed Outlook — Fundamental
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Brookfield Asset Management... 
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements
Madrigal’s MGL-3196 NASH abstract selected for oral presentation in the presidential plenary clinical session of The Liver Meeting® 2018 during the American Association for the Study of Liver Diseases... 
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Prices Public Offering of Common Stock
Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of... 
From GlobeNewswire News Releases
Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of... 
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.